BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 28846491)

  • 1. Human papilloma virus vaccine for low and middle income countries: A step too soon?
    Jindal HA; Kaur A; Murugan S
    Hum Vaccin Immunother; 2017 Nov; 13(11):2723-2725. PubMed ID: 28846491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
    Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
    Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
    Poljak M
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
    Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus: science and technologies for the elimination of cervical cancer.
    Bosch FX
    Expert Opin Pharmacother; 2011 Oct; 12(14):2189-204. PubMed ID: 21756205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What works for human papillomavirus vaccine introduction in low and middle-income countries?
    Howard N; Gallagher KE; Mounier-Jack S; Burchett HED; Kabakama S; LaMontagne DS; Watson-Jones D
    Papillomavirus Res; 2017 Dec; 4():22-25. PubMed ID: 29179865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
    Khaliq SA; Shyum Naqvi SB; Fatima A
    Pak J Pharm Sci; 2012 Oct; 25(4):763-72. PubMed ID: 23009992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
    Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
    BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of human papillomavirus immunization in the developing world.
    Kane MA; Serrano B; de Sanjosé S; Wittet S
    Vaccine; 2012 Nov; 30 Suppl 5():F192-200. PubMed ID: 23199963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current global status & impact of human papillomavirus vaccination: Implications for India.
    Sankaranarayanan R; Bhatla N; Basu P
    Indian J Med Res; 2016 Aug; 144(2):169-180. PubMed ID: 27934795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Realities of alternative HPV vaccination schedules.
    Stanley M
    Salud Publica Mex; 2018; 60(6):617-620. PubMed ID: 30699265
    [No Abstract]   [Full Text] [Related]  

  • 18. Options for design of real-world impact studies of single-dose vaccine schedules.
    Franceschi S; Clifford GM; Baussano I
    Vaccine; 2018 Aug; 36(32 Pt A):4816-4822. PubMed ID: 29571973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlates of human papillomavirus vaccine coverage: a state-level analysis.
    Moss JL; Reiter PL; Brewer NT
    Sex Transm Dis; 2015 Feb; 42(2):71-5. PubMed ID: 25585064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cervical cancer and HPV vaccines in developing countries.
    Karimi Zarchi M; Behtash N; Chiti Z; Kargar S
    Asian Pac J Cancer Prev; 2009; 10(6):969-74. PubMed ID: 20192568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.